Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Patient Preference
Conditions
Brief summary
It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial infections, and reduced treatment discomfort. However, this hypothesis has not been formally studied in a controlled setting. This study aims to address this evidence gap and evaluate patient, primary caregiver (carer), and clinician treatment preference between oral decitabine/cedazuridine and SC AZA in the treatment of adult patients with International Prognostic Scoring System-Revised (IPSS-R) intermediate, IPSS intermediate-2, or high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), or low-blast (LB) acute myeloid leukemia (AML) and thereby lend further credibility to the clinical, economic, and patient value of oral decitabine/cedazuridine.
Interventions
DRUGSubcutaneous azacitidine
Subcutaneous azacitidine, 75mg/m2, 7 days
Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
Sponsors
Otsuka Australia Pharmaceutical Pty Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For Patients: Patients are eligible to be included in the study only if all of the following criteria apply at any time starting from Screening up to Day 1 prior to study treatment administration: * Patients must be 18 years of age or older. * IPSS-R defined intermediate MDS, IPSS defined intermediate 2 or high-risk MDS, LB AML or CMML (with symptoms), as confirmed by recent full blood examination, bone marrow biopsy, and cytogenetic testing. NOTE: IPSS-R defined intermediate MDS patients are limited to less than 50% of enrolled patients. * Life expectancy of at least 6 months. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 inclusive. * Patient must be able to co-operate and complete tasks (including tasks such as electronic questionnaires on digital devices) over the following 4 months. Inclusion Criteria: For Patients: Patients are eligible to be included in the study only if all of the following criteria apply at any time starting from Screening up to Day 1 prior to study treatment administration: * Patients must be 18 years of age or older. * IPSS-R defined intermediate MDS, IPSS defined intermediate 2 or high-risk MDS, LB AML or CMML (with symptoms), as confirmed by recent full blood examination, bone marrow biopsy, and cytogenetic testing. NOTE: IPSS-R defined intermediate MDS patients are limited to less than 50% of enrolled patients. * Life expectancy of at least 6 months. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 inclusive. * Patient must be able to co-operate and complete tasks (including tasks such as electronic questionnaires on digital devices) over the following 4 months. * Patient must be able to identify a carer to participate in completing the cTPMQ. For Carers: • Primary carer of a patient meeting all of the inclusion criteria (ie, a patient who meets criteria defined above). For Clinicians: • Clinician treating patients meeting all of the inclusion criteria (ie, treats patients who meet criteria defined above).
Exclusion criteria
For Patients: Patients are excluded from the study if any of the following criteria apply: * Patients with known hypersensitivity to the study treatments oral decitabine/cedazuridine or azacitidine. * Patients with advanced malignant hepatic tumors. * Patients with severe renal impairment (creatinine clearance \<30 mL/min). * Patients who have received hypomethylating agents (HMA) previously. * Patients who are receiving lenalidomide or are receiving other therapies outside of standard of care (SOC). * Receipt of any immunotherapy, any conventional or investigational systemic anti-cancer therapy within 5 half-lives of the drug, or within 4 weeks prior to the first dose of study treatment (whichever is longer). * Any medical, psychological, social, or other condition which in the view of the Investigator is likely to interfere with the study, compliance, or put the patient at risk. * Participants who are not fluent in English, or who cannot read or write in English will be excluded from the study. For Carers: Carers are excluded from the study if any of the following criteria apply: * They are a carer of a patient who meets any of the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the patient treatment preference in myelodysplasia questionnaire (pTPMQ) | Prior to initiation of Cycle 3 (each cycle is 28 days) |
| Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the pTPMQ | Prior to initiation of Cycle 5 (each cycle is 28 days) |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of carers reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the cTPMQ | Prior to initiation of Cycle 5 (each cycle is 28 days) |
| Proportion of clinicians reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the medical treatment preference in myelodysplasia questionnaire (mTPMQ) | Prior to initiation of Cycle 4 (each cycle is 28 days) |
| Proportion of clinicians reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the mTPMQ | End of Study (EOS) Day 28 |
| Proportion of clinicians choosing oral decitabine/cedazuridine vs subcutaneous azacitidine for continuation of treatment and reasons for the treatment choice based on the mTPMQ | Cycle 5, Day 1 (each cycle is 28 days) |
| Difference in quality of life between oral decitabine/cedazuridine and Subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients | Cycle 4, Day 5 (each cycle is 28 days) |
| Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients | Cycle 1, Day 1 (each cycle is 28 days) |
| Difference in quality of life between oral decitabine/cedazuridine and Subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients | Cycle 4, Day 5 (each cycle is 28 days) |
| The difference in the incidence of treatment discontinuation and reasons for treatment discontinuation | Baseline (pre-intervention) through to study completion (up to 6 cycles of treatment where each cycle is 28 days) |
| Incidence and severity of adverse events upon study physician discretion. | Baseline (pre-intervention) through to study completion (up to 6 cycles of treatment where each cycle is 28 days) |
| Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients | Cycle 1, Day 1 (each cycle is 28 days) |
| Proportion of carers reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the carer treatment preference in myelodysplasia questionnaire (cTPMQ) | Prior to initiation of Cycle 3 (each cycle is 28 days) |
Countries
Australia, New Zealand
Outcome results
None listed